Compare Stocks

→ Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACST Acasti Pharma	$2.88 +1.1%	$3.32	$1.72 ▼ $3.84	$27.07M	1.49	26,505 shs	4,477 shs
MVF BlackRock MuniVest Fund	$6.82	$6.98	$5.85 ▼ $7.19	$439.21M	0.46	159,275 shs	222,672 shs
RVX Resverlogix	C$0.06	C$0.06	C$0.05 ▼ C$0.16	C$16.33M	0.78	37,265 shs	36,650 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACST Acasti Pharma	-0.70%	-15.18%	-16.18%	+16.33%	+2.15%
MVF BlackRock MuniVest Fund	0.00%	+0.22%	-2.99%	-0.15%	+0.74%
RVX Resverlogix	0.00%	-8.33%	-8.33%	-15.38%	-66.67%

Exposed: 10 CENT Crypto to Explode April 20th? (Ad)

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACST Acasti Pharma	2.5257 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.8	1.3
MVF BlackRock MuniVest Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACST Acasti Pharma	3.00	Buy	$6.00	108.33% Upside
MVF BlackRock MuniVest Fund	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest HZD, BOT, MVF, RVX, and ACST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
2/7/2024	ACST Acasti Pharma	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACST Acasti Pharma	N/A	N/A	N/A	N/A	$9.14 per share	N/A
MVF BlackRock MuniVest Fund	N/A	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	C$0.00 per share	132.50	C($0.26) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACST Acasti Pharma	-$42.43M	-$5.08	N/A	N/A	N/A	N/A	-13.18%	-11.32%	6/28/2024 (Estimated)
MVF BlackRock MuniVest Fund	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RVX Resverlogix	-C$12.82M	-C$0.05	N/A	∞	N/A	N/A	N/A	-37.10%	5/9/2024 (Estimated)

Latest HZD, BOT, MVF, RVX, and ACST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/12/2024	12/31/2023	ACST Acasti Pharma	-$0.23	-$0.21	+$0.02	-$0.21	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACST Acasti Pharma	N/A	N/A	N/A	N/A	N/A
MVF BlackRock MuniVest Fund	$0.30	4.40%	N/A	N/A	N/A
RVX Resverlogix	N/A	N/A	N/A	N/A	N/A

Latest HZD, BOT, MVF, RVX, and ACST Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/1/2024	MVF BlackRock MuniVest Fund	monthly	$0.03	5.2%	4/12/2024	4/15/2024	5/1/2024
3/1/2024	MVF BlackRock MuniVest Fund	monthly	$0.03	5.1%	3/14/2024	3/15/2024	4/1/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACST Acasti Pharma	N/A	15.19	15.19
MVF BlackRock MuniVest Fund	N/A	N/A	N/A
RVX Resverlogix	N/A	0.11	0.04

Ownership

Institutional Ownership

Company	Institutional Ownership
ACST Acasti Pharma	6.08%
MVF BlackRock MuniVest Fund	48.16%
RVX Resverlogix	N/A

Insider Ownership

Company	Insider Ownership
ACST Acasti Pharma	13.51%
MVF BlackRock MuniVest Fund	1.00%
RVX Resverlogix	43.19%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ACST Acasti Pharma	32	9.40 million	8.13 million	Not Optionable
MVF BlackRock MuniVest Fund	147,000	64.40 million	63.75 million	Not Optionable
RVX Resverlogix	19	272.17 million	N/A	Not Optionable

HZD, BOT, MVF, RVX, and ACST Headlines

Source	Headline
	Resverlogix Announces Change to Its Board of Directors finance.yahoo.com - February 21 at 8:02 PM
	Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits finance.yahoo.com - January 11 at 10:03 AM
	Closing Bell: Resverlogix Corp flat on Tuesday (RVX) theglobeandmail.com - January 4 at 6:16 PM
	Resverlogix Corp. (RVX) Earnings Dates & Reports investing.com - December 19 at 7:28 PM
	Resverlogix Corp RVXCF morningstar.com - November 18 at 5:49 PM
	Resverlogix Corp RVX morningstar.com - November 1 at 11:18 AM
	Resverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX) theglobeandmail.com - October 18 at 7:46 AM
	Resverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy finanznachrichten.de - October 4 at 10:11 AM
	Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy finance.yahoo.com - October 4 at 10:11 AM
	Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight finance.yahoo.com - September 26 at 8:50 PM
	Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes finance.yahoo.com - August 29 at 10:13 AM
	Closing Bell: Resverlogix Corp up on Wednesday (RVX) theglobeandmail.com - August 24 at 3:35 PM
	Closing Bell: Resverlogix Corp flat on Monday (RVX) theglobeandmail.com - August 14 at 10:02 PM
	Closing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A) theglobeandmail.com - July 12 at 7:21 AM
	Resverlogix Announces Warrant Repricing and One-Year Extension finance.yahoo.com - June 29 at 11:09 PM
	Resverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders finanznachrichten.de - June 20 at 7:31 PM
	Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders finance.yahoo.com - June 20 at 7:31 PM
	Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients finance.yahoo.com - June 12 at 6:42 PM
	Canadian Investment Regulatory Organization Trading Halt - RVX.WT.A finance.yahoo.com - June 7 at 1:32 PM
	Closing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A) theglobeandmail.com - June 6 at 10:49 AM
	Closing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A) theglobeandmail.com - May 25 at 12:52 AM
	CBOE RUSSELL 2000 VOLATILITY IN (^RVX) finance.yahoo.com - May 18 at 12:38 AM
	Bromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzz news.google.com - May 13 at 3:47 PM
	Resverlogix : MD&A Q1 2023 - Marketscreener.com news.google.com - May 12 at 3:50 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UiPath Cuts Q1 and Raises Full Year Guidance
March 26, 2024 7:41 AM
View UiPath Cuts Q1 and Raises Full Year Guidance
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
March 28, 2024 9:25 AM
View Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024 7:22 AM
View 7 Stocks That Will Drive the Weight Loss Drugs Market
Abbott Laboratories Outlook is Healthy: Buy the Dip
April 17, 2024 10:41 AM
View Abbott Laboratories Outlook is Healthy: Buy the Dip
3 High-Yield Stocks In Rebound Mode: How High Can They Go?
April 11, 2024 7:25 AM
View 3 High-Yield Stocks In Rebound Mode: How High Can They Go?

All Headlines

Company Descriptions

Acasti Pharma

NASDAQ:ACST

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

BlackRock MuniVest Fund

NYSE:MVF

BlackRock MuniVest Fund, Inc. is a closed-ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in the fixed income markets of the United States. It primarily invests in investment grade, long term municipal obligations that are exempt from federal income taxes. The fund seeks to invest in securities with maturities of more than ten years. BlackRock MuniVest Fund, Inc. was formed on September 29, 1988 and is domiciled in the United States.

Resverlogix

TSE:RVX

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial